Actively Recruiting
Continuation Study Providing Long-Term Access to Encorafenib and Binimetinib for Participants in Previous Clinical Trials
Led by Pfizer · Updated on 2026-10-19
210
Participants Needed
77
Research Sites
152 weeks
Total Duration
AI-Summary
What This Trial Is About
This clinical trial, known as the FLOTILLA study, provides continued access and safety follow-up for participants who were part of previous clinical trials involving encorafenib andor binimetinib. It is designed for individuals who are still benefiting from these study medicines, as determined by their study doctor. The study is conducted under a Master Protocol and includes multiple continuation sub-studies for participants from various earlier trials. Participants will receive the same study treatment as in their prior parent study, maintaining the same dose and frequency of encorafenib, binimetinib, or other related medicines such as vemurafenib, ribociclib, cetuximab, pembrolizumab, nivolumab, and chemotherapy drugs. Treatments are administered orally or intravenously according to the specific drug schedule. Treatment may continue for up to about five years while participants remain on therapy and benefit clinically. During the study, participants will be regularly monitored for safety, including tracking adverse events and serious adverse events that could lead to stopping the study drug. Researchers will assess these safety measures from the start of participation through approximately five years. The study aims to closely follow participants health and treatment tolerability throughout this extended period, with ongoing evaluations and follow-up visits.
CONDITIONS
Brief Title
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here